ANDAINTRAVENOUSSOLUTION
Approved
Oct 2025
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
GALLIUM GA 68 EDOTREOTIDE (gallium ga-68 edotreotide) by United Therapeutics is 68 dotatoc binds to somatostatin receptors, with highest affinity (k i = 2. First approved in 2025.
Drug data last refreshed 1w ago
Mechanism of Action
68 DOTATOC binds to somatostatin receptors, with highest affinity (K i = 2.5± 0.5 nanomolar) for subtype 2 receptors (sstr2). Ga 68 DOTATOC binds to cells that express somatostatin receptors including malignant neuroendocrine cells, which overexpress sstr2 receptors. Gallium 68 is a β+ emitting…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
United Therapeutics
Worked on GALLIUM GA 68 EDOTREOTIDE at United Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.